Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -6537.01% is 25% below its 5-year average of -5215.04%, near the high end of its 5-year range (-113616.67%–100.00%).
41.43% below its 12-month average of -4621.96%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -337.80%.
GROSS MARGIN
-6537.01%
GROSS MARGIN AVG TTM
-4621.96%
GROSS MARGIN AVG 3Y
-4083.08%
GROSS MARGIN AVG 5Y
-5215.04%
GROSS MARGIN AVG 10Y
-5308.65%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-41.43%
CURRENT VS 3Y AVG
-60.10%
CURRENT VS 5Y AVG
-25.35%
CURRENT VS 10Y AVG
-23.14%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
59.92%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
-11008.65%
vs the sector median at left
CRISPR Therapeutics AG
Market Cap
$5.35B
Gross Margin
-6537.01%
TTM Avg
-4621.96%
3Y Avg
-4083.08%
5Y Avg
-5215.04%
Market Cap
$5.10B
Gross Margin
49.52%
TTM Avg
48.04%
3Y Avg
46.91%
5Y Avg
45.73%
Market Cap
$5.61B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-67.67%
5Y Avg
-188.00%
Market Cap
$6.47B
Gross Margin
73.84%
TTM Avg
76.65%
3Y Avg
78.21%
5Y Avg
76.94%
Market Cap
$2.76B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$8.02B
Gross Margin
14.38%
TTM Avg
17.24%
3Y Avg
38.82%
5Y Avg
59.22%
Market Cap
$2.52B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.35B | -6537.01% | -4621.96% | -4083.08% | -5215.04% |
| Doximity, Inc. (DOCS)vs › | $5.22B | 88.07% | 89.65% | 88.97% | 88.20% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 49.52% | 48.04% | 46.91% | 45.73% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | 0.00% | 0.00% | -67.67% | -188.00% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | 73.84% | 76.65% | 78.21% | 76.94% |
| Chemed Corporation (CHE)vs › | $6.63B | 30.44% | 32.55% | 34.06% | 34.32% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 58.69% | 59.64% | 63.22% | 64.62% |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | 14.38% | 17.24% | 38.82% | 59.22% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | 84.05% | -197.31% | -176.53% | -71811.06% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -61.96% | -19.42% | -14.39% | 23.74% |
Gross Margin
-6537.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -337.80% |
| 2026-03-31 | -3346.43% |
| 2025-12-31 | -6770.83% |
| 2025-09-30 | -7177.05% |
| 2025-06-30 | -5477.69% |
| 2025-03-31 | -6548.44% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | -2550.00% |
| 2024-06-30 | -10920.50% |
| 2024-03-31 | -10177.58% |
| 2023-12-31 | 90.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 36.23% |
| 2023-03-31 | 57.81% |
| 2022-12-31 | -113616.67% |
| 2022-09-30 | -41239.36% |
| 2022-06-30 | -21369.62% |
| 2022-03-31 | -17116.85% |
| 2021-12-31 | -945.96% |
| 2021-09-30 | -6727.96% |
| 2021-06-30 | 97.01% |
| 2021-03-31 | -9773.76% |
| 2020-12-31 | -22160.81% |
| 2020-09-30 | -47878.38% |
| 2020-06-30 | -134854.55% |
| 2020-03-31 | -34417.83% |
| 2019-12-31 | 36.69% |
| 2019-09-30 | 72.99% |
| 2019-06-30 | -12331.76% |
| 2019-03-31 | -8698.78% |
| 2018-12-31 | -24944.35% |
| 2018-09-30 | -6972.82% |
| 2018-06-30 | -2255.97% |
| 2018-03-31 | -1337.33% |
| 2017-12-31 | 38.04% |
| 2017-09-30 | -647.59% |
| 2017-06-30 | -377.95% |
| 2017-03-31 | -447.72% |
| 2016-12-31 | -564.33% |
| 2016-09-30 | -678.05% |
| 2016-06-30 | -982.01% |
| 2016-03-31 | -1163.03% |
| 2015-12-31 | -2399.60% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
